SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myriad Genetics, Inc. (MYGN)
MYGN 5.680-4.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1723)11/28/2005 1:25:42 PM
From: NeuroInvestment  Read Replies (2) of 2355
 
I had never looked at this board before, but in preparing an AD review, I was looking for alternative points of view, given what I thought was a very strange clinical program for Flurizan. So this is where Rick H has been. Anyways, it was useful and entertaining going back through a few months of posts, so here are a couple of thoughts about the Flurizan program:

1) 86 patients enrolled in the follow-on, they had to be getting drug in the main trial to be eligible. Only 41 completed the six months of followon reported, which seems strikingly low to me. 23 were in the 800mg group that had this 'miraculous' improvement in ADAS-cog. Looks like the nonresponders gave up and quit, so this sample is highly skewed. I do not take this as indicating some rescue of the Alzheimer's 'penumbra' of cells on the edge.

2) Myriad doesnt appear to have taken its own numbers seriously either. If there were some cell resurrection/recovery process going on in the 12-18 month area, in contrast to the converging lines of 9-12 months, you'd think they'd like to use that in Phase III. Instead, it's a 12 month study. In contrast to the 18 month timeframes being used in Phase III by Neurochem and Voyager.

Based on very little review, Myriad looks like an interesting predictive medicine company.

Harry
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News